Feedback
Myeloid Malignancies Somatic Mutation and Copy Number Analysis Panel
2012182
Ordering Recommendation

Detects important genomic abnormalities in acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MDS/MPN neoplasms that may have diagnostic, prognostic, and/or therapeutic significance:
• Loss/gain of DNA
• Loss of heterozygosity (LOH)
• Single gene mutations (substitutions and small insertions and deletions)

Mnemonic
MYE CMANGS
Methodology
Massively Parallel Sequencing/Genomic Microarray (Oligo-SNP Array)
Performed
Varies
Reported
14-16 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Lavender (K2EDTA) OR Bone Marrow (EDTA). 
Specimen Preparation
Do not freeze. Transport 5 mL whole blood. (Min: 1 mL) OR Transport 3 mL bone marrow. (Min: 1 mL)Separate specimens must be submitted when multiple tests are ordered. 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Serum, plasma or tissue. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens. 
Remarks
 
Stability
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Refer to report.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
The diagnosis under consideration is required information to order this test. Genes tested: ANKRD26, ASXL1, ASXL2, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CEBPA, CSF3R, CUX1*, DDX41, DNMT1*, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HNRNPK, IDH1, IDH2, IL7R, JAK1, JAK2, JAK3, KDM6A*, KIT, KMT2A, KRAS, LUC7L2, MPL, NOTCH1, NPM1*, NRAS, NSD1, PHF6, PIGA, PRPF40B, PRPF8, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B*, SUZ12*, TET2, TP53, U2AF1, U2AF2, WT1, ZRSR2.

* - One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information.
Hotline History
View Hotline History
CPT Code(s)
81406; 81455
Components
Component Test Code*Component Chart NameLOINC
2006326Cytogenomic Microarray SNP - Oncology
2011118Myeloid Malignancy Proposed Diagnosis
2011119Myeloid Malignancies Panel Specimen31208-2
2011120Myeloid Malignancies Panel Interp35474-6
2012183Myeloid Panel Summary
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Acute myeloid leukemia, AML
  • Aplastic Anemia
  • Atypical chronic myelogenous leukemia, aCML
  • Chronic eosinophilic leukemia not otherwise specified
  • Chronic myelogenous leukemia, BCR-ABL1 positive, CML
  • Chronic myelomonocytic leukemia, CMML
  • Chronic neutrophilic leukemia, CNL
  • Genomic microarray
  • Juvenile myelomonocytic leukemia, JMML
  • Mastocytosis
  • Myelodysplastic syndrome with isolated del(5q)
  • Myelodysplastic syndromes, MDS
  • Myelodysplastic/Myeloproliferative neoplasm, MDS/MPN
  • Myeloproliferative neoplasm, essential thrombocythemia, MPN-ET
  • Myeloproliferative neoplasm, MPN
  • Myeloproliferative neoplasm, polycythemia vera, MPN-PV
  • Myeloproliferative neoplasm, primary myelofibrosis, MPN-PMF
  • Oligo-SNP array
  • Refractory anemia with excess blasts, RAEB
  • Refractory anemia with ring sideroblasts associated with marked thrombocytosis, RARS-T
  • Refractory anemia with ring sideroblasts, RARS
  • Refractory cytopenia with multilineage dysplasia, RCMD
  • Refractory cytopenia with unilineage dysplasia, RCUD